{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"Using a traditional 3+3 dose escalation design, successive cohorts of subjects will receive a fixed dose level of the drug combination. The MTD is defined as the highest dose level at which ≤1 of 6 subjects experiences a dose-limiting toxicity (DLT) assessed by NCI CTCAE v4.0. DLT is defined as any of the following that are determined to be related to study treatment during Cycle 1:\n\nGrade 4 neutropenia for \\>7 days, Febrile neutropenia, Grade 3 thrombocytopenia with ≥ Grade 2 bleeding, Grade 4 thrombocytopenia \\> 7 days, ≥ Grade 2 neuropathy with uncontrolled pain, ≥ Grade 3 non-hematologic drug-related toxicity (excluding alopecia), despite optimal supportive care lasting \\>72 hours or requiring a dose reduction in the first cycle and Patients who are unable to receive 75% of the required doses of both agents secondary to toxicity. Number of Participants With such Dose Limiting Toxicities (DLT) at each level are reported here.","groups":[{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 27 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 27 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19\n\npanobinostat: Specified dose on specified days\n\ncarfilzomib: Specified dose on specified days","id":"OG000","title":"Dose Level 1"},{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 36 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 36 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19\n\npanobinostat: Specified dose on specified days\n\ncarfilzomib: Specified dose on specified days","id":"OG001","title":"Dose Level 2"},{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 45 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19\n\npanobinostat: Specified dose on specified days\n\ncarfilzomib: Specified dose on specified days","id":"OG002","title":"Dose Level 3"},{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 45 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19\n\npanobinostat: Specified dose on specified days\n\ncarfilzomib: Specified dose on specified days","id":"OG003","title":"Dose Level 4"},{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 56 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19","id":"OG004","title":"Dose Level 5"},{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 56 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19\n\npanobinostat: Specified dose on specified days\n\ncarfilzomib: Specified dose on specified days","id":"OG005","title":"Dose Level 6"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Includes all Phase 1 patients receiving assigned study dosing","reportingStatus":"POSTED","timeFrame":"28 days from the start of study treatment","title":"Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage","type":"PRIMARY","unitOfMeasure":"Participants"}